Appeals Court Checks FDA On Its 510(k) Rescission Authority
This article was originally published in The Gray Sheet
Executive Summary
In a 2-1 opinion, a federal appeals court ruled that FDA can’t use rescission to reverse a 510(k) clearance if the more time-consuming device reclassification process can accomplish the same ends. The decision sends a collagen knee scaffold device, which previously caused major contention inside FDA, back to the agency for a decision, but more court review might be ahead.
You may also be interested in...
An FDA Age-Based Predicate Policy Would Be Arbitrary, Reg Experts Complain
The device industry is still sorting out the implications of US FDA's recent proposals to make what the agency describes as a major update to the 510(k) process. But regulatory experts say the agency's focus on finding an age-based cut-off for 510(k) predicate devices is misguided, and some argue that Congress should need to sign off on any of the floated policies.
Device Center Discord: 510(k) Review Process Is Flash Point At CDRH
Details trickling into the public sphere about CDRH's device review process reveal heightened tension between reviewers and management over the proper response to a 510(k) submission
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.